Drug Trial Radar · NCT07602842
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
132
Planned (sponsor's estimate)
Start
Jul 8, 2026
Primary completion
Jun 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- InduPro, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of IDP-001 in participants with advanced or metastatic squamous and non-squamous NSCLC and other squamous cell solid tumors (for example, head and neck, esophageal, cervical, cutaneous).
Conditions
- Advanced Solid Tumor
- Metastatic Solid Tumor
- Head and Neck Squamous Cell Carcinoma
- Cutaneous Squamous Cell Carcinoma
- Squamous Cell Carcinoma of the Cervix
- Non Squamous Non Small Cell Lung Cancer
- Squamous Cell Carcinoma of the Esophagus
- Squamous Cell Carcinoma of the Anus
- Squamous Cell Carcinoma
Interventions
IDP-001Drug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 Part 1: Number of Participants with Dose Limiting Toxicities (DLTs) during Cycle 1Time frame: 3 weeks
- Phase 1 Part 1: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and AEs Leading to Dose Reduction, Dose Interruption, and Dose DiscontinuationTime frame: Approximately 6 months
- Phase 1 Part 2: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by InvestigatorTime frame: Approximately 6 months
- Phase 1 Part 2: Duration of Response (DOR) per RECIST Version 1.1 as Assessed by InvestigatorTime frame: Approximately 6 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
START Los Angeles
Los Angeles, California · Recruiting
Florida Cancer Specialists
Sarasota, Florida · Recruiting
Community Cancer Center North
Indianapolis, Indiana · Recruiting
Roswell Park Cancer Institute
Buffalo, New York · Recruiting
START New York Long Island
Lake Success, New York · Recruiting
START Dallas Forth Worth
Fort Worth, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.